No abstract available
Keywords: CALR; JAK inhibition; myeloproliferative disease.
Publication types
- Letter
- Practice Guideline
MeSH terms
- Anemia / chemically induced
- Humans
- Janus Kinase 1 / antagonists & inhibitors*
- Janus Kinase 2 / antagonists & inhibitors*
- Maximum Tolerated Dose
- Nitriles
- Primary Myelofibrosis / complications
- Primary Myelofibrosis / drug therapy*
- Primary Myelofibrosis / enzymology
- Protein Kinase Inhibitors / administration & dosage
- Protein Kinase Inhibitors / adverse effects
- Protein Kinase Inhibitors / therapeutic use*
- Pyrazoles / adverse effects
- Pyrazoles / therapeutic use*
- Pyrimidines
- Recurrence
- Splenomegaly / drug therapy
- Splenomegaly / etiology
- Symptom Assessment
- Thrombocytopenia / chemically induced
Substances
- Nitriles
- Protein Kinase Inhibitors
- Pyrazoles
- Pyrimidines
- ruxolitinib
- JAK2 protein, human
- Janus Kinase 1
- Janus Kinase 2